Feb 11, 2026 09:17AM Psyence BioMed settles shareholder litigation for $1.5 million

Dec 19, 2025 07:01AM Psyence BioMed gets approval for psilocybin product in phase IIb trial

Nov 25, 2025 07:05AM Psyence BioMed launches psilocybin longevity research program

Nov 20, 2025 07:01AM Psyence BioMed secures ibogaine supply for clinical development

Nov 6, 2025 07:01AM Psyence BioMed doses patients in Phase IIb psilocybin trial

Oct 14, 2025 04:09PM Psyence Biomedical (PBM) files for 50M share offering by selling stockholders

Aug 4, 2025 09:40AM Psyence BioMed advances clinical trials and reports $11.4M cash

Jul 31, 2025 07:32AM Psyence BioMed partner produces high-purity ibogaine extract

Jun 18, 2025 08:30AM Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025 08:03AM Psyence Biomedical (PBM) Regains Nasdaq Compliance

Jun 17, 2025 08:00AM Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025 07:32AM Psyence Biomedical (PBM) Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025 07:30AM Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025 07:34AM Psyence Biomedical (PBM) Sets May 5th as Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025 07:30AM Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025 07:17PM Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 15, 2025 08:33AM Psyence Biomedical (PBM) Announces $500K Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 15, 2025 08:30AM Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025 08:00AM Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025 08:00AM Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025 08:36AM Psyence Biomedical (PBM) appoints Dr. Dan Stein to SAB

Mar 18, 2025 08:30AM Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025 11:25AM Psyence Biomedical Ltd. (PBM) appoints Albert Garcia-Romeu as Chair of new Scientific Advisory Board

Dec 23, 2024 08:03AM Psyence Biomedical (PBM) Prices 1M Share Offering at $2/sh

Dec 23, 2024 07:31AM Psyence Biomedical (PBM) Regains Nasdaq Compliance

Dec 17, 2024 07:30AM Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Nov 20, 2024 07:32AM Psyence Biomedical (PBM) Announces Favorable Result of Nasdaq Listing Qualifications Hearing

Nov 19, 2024 04:05PM Psyence Biomedical (PBM) Sets November 26 as Effective Date of 1:75 Reverse Share Split

Oct 24, 2024 07:00AM Psyence Biomedical (PBM) Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 4, 2024 04:07PM Psyence Biomedical (PBM) Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 19, 2024 07:30AM Psyence Biomedical (PBM) to Acquire Stake in PsyLabs

Sep 13, 2024 04:31PM Psyence Biomedical (PBM) Receives Nasdaq Staff Delisting Determination

Sep 6, 2024 07:30AM Psyence Biomedical (PBM) Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Sep 4, 2024 07:31AM Psyence Biomedical (PBM) Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin